



MEDIA CONTACT :

Lisa Kornblatt
SS|PR
847-415-9330
lkornblatt@sspr.com

**Stryker's 2010 Innovator of the Year Brian Hess Joins InVivo
Therapeutics as Director of Product Development**

*Moves from Stryker to Translate InVivo's Biomaterials for Acute and Chronic Neurological
Injuries to Market*

CAMBRIDGE, Mass. (February 22, 2012) – InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), announced today that former Stryker biomaterials product development specialist, Brian Hess, has joined InVivo as its Director of Product Development.

As Director of Product Development, Hess will be managing, developing and maintaining the pipeline for the entire portfolio of InVivo products. Hess will lead the translation of InVivo's technologies from research and development through clinical trials and into production manufacturing by developing specifications, protocols and reports.

Prior to joining InVivo Therapeutics, Hess spent the past eight years at Stryker developing biomaterial technologies for the orthopedic market, and he has led multiple product development teams through the FDA process. Hess was instrumental in developing HydroSet™, an injectable calcium phosphate based bone substitute, from concept to product launch. The product has become the market-leading bone scaffold, and Stryker awarded Hess and his team with "Best Technology" and "Best Team Synergy" for their work on this critical product.

"I've been impressed with the cutting-edge work from the InVivo Therapeutics team on the development of the biopolymer scaffold technologies and the impact it can have on the future of neurological treatments," Hess said. "I am honored to join the team to help bring this product and others in the research and development phase to market."

Hess also won several research and development awards during his tenure at Stryker. Most notably he was named "Co-Innovator of the Year" in 2010 within Stryker Orthopedics for his work on a novel bone adhesive technology that has the potential to replace metal fixation in the body and revolutionize the orthopedic fixation market. He spent the past three years working with his team demonstrating its feasibility and safe use as his program grew to a team of more than 25 engineers and scientists.

InVivo Chief Executive Officer Frank Reynolds said, “We believe Brian’s past successes in the medical device industry will lead the commercialization of the three products we intend to have under review at FDA this year, as well as help to bring our portfolio of products for other neurological conditions successfully to the market in the coming years.”

For more information about InVivo Therapeutics’ technologies, visit www.invivotherapeutics.com.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is focused on utilizing polymers as a platform technology to develop treatments to improve function in individuals paralyzed as a result of traumatic spinal cord injury. The company was founded in 2005 on the basis of proprietary technology co-invented by Robert Langer, ScD. Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who is affiliated with Massachusetts General Hospital. In 2011, the company earned the prestigious David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. The publicly traded company is headquartered in Cambridge, Mass. For more details, visit www.invivotherapeutics.com.

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements within the meaning of the federal securities laws. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company’s ability to sell additional shares of common stock and warrants to purchase common stock at additional closings, the Company’s ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company’s products and technology in connection with spinal cord injuries; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company’s business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our Form 10-K and Form 10-Qs and our current reports on Form 8-K. We do not undertake to update these forward-looking statements made by us.

#